Biotest AG: Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US
Biotest AG / Key word(s): Miscellaneous
Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma collection centers in the US now eighteen.
"This facility represents another milestone in our continued efforts to strengthen our network of plasma collection centers and further reinforces our commitment to better serve the thousands of patients world-wide that rely on plasma based therapies" said Jordan Siegel, Biotest Pharmaceuticals Corporation (BPC), Chief Executive Officer. BPC is a wholly owned subsidiary of Biotest AG. Moreover, Biotest is pleased to announce the relocation of its plasma collection in San Antonio, Texas. The 18,000 square foot state-of-the-art facility officially opened its doors for business on Sunday, March 29th 2015. The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas, such as Bivigam(R) (Immune Globulin Intravenous (Human), 10% Liquid) and Nabi-HB(R) (Hepatitis B Immune Globulin (Human)). Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 2015-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
Language: | English | |
Company: | Biotest AG | |
Landsteinerstraße 5 | ||
63303 Dreieich | ||
Germany | ||
Phone: | 0 61 03 - 8 01-0 | |
Fax: | 0 61 03 - 8 01-150 | |
E-mail: | investor_relations@biotest.de | |
Internet: | http://www.biotest.de | |
ISIN: | DE0005227235, DE0005227201 | |
WKN: | 522723, 522720 | |
Indices: | SDAX | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart | |
End of News | DGAP News-Service |
342693 2015-04-13 |